List of Excipients in Branded Drug ADVIL MULTI-SYMPTOM COLD AND FLU

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL MULTI-SYMPTOM COLD AND FLU	chlorpheniramine maleate, ibuprofen, phenylephrine hcl	0573-0190	ACESULFAME POTASSIUM
Haleon US Holdings LLC	ADVIL MULTI-SYMPTOM COLD AND FLU	chlorpheniramine maleate, ibuprofen, phenylephrine hcl	0573-0190	CARNAUBA WAX
Haleon US Holdings LLC	ADVIL MULTI-SYMPTOM COLD AND FLU	chlorpheniramine maleate, ibuprofen, phenylephrine hcl	0573-0190	CELLULOSE, MICROCRYSTALLINE

Advil Multi-Symptom Cold and Flu Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Advil Multi-Symptom Cold and Flu is a U.S. over-the-counter combination product built around ibuprofen, phenylephrine hydrochloride, and chlorpheniramine maleate. Its excipient strategy must support three active ingredients with different stability, solubility, taste, and release requirements. The largest commercial opportunities are reformulated liquid-filled capsules, alcohol-free liquid products, pediatric or age-segmented presentations, sugar-free dosage forms, and packaging that improves adherence and reduces dosing errors.

What is the active-ingredient profile of Advil Multi-Symptom Cold and Flu?

The U.S. caplet and liquid-filled capsule products are generally positioned as multi-symptom cold and flu treatments containing:

Active ingredient	Typical labeled amount per dosage unit	Functional purpose
Ibuprofen	200 mg	Pain relief and fever reduction
Phenylephrine hydrochloride	10 mg	Nasal decongestion
Chlorpheniramine maleate	2 mg	Antihistamine for runny nose and sneezing

The product is marketed for temporary relief of fever, headache, minor aches, nasal congestion, runny nose, and sneezing. Exact dosage form, inactive ingredients, warnings, and labeling vary by NDC and presentation. The FDA Drug Facts label is the controlling commercial and regulatory document for each product configuration.[1]

The combination creates a formulation problem: ibuprofen is a poorly water-soluble, relatively high-dose active, while phenylephrine hydrochloride and chlorpheniramine maleate are lower-dose, more water-compatible ingredients. The formulation must also account for chlorpheniramine’s sedating profile and ibuprofen’s gastrointestinal and renal warnings.

What excipients are most important in the formulation?

The core excipient strategy is to separate physical compatibility, improve manufacturability, protect stability, and control consumer experience.

Solid oral dosage forms

A caplet or tablet formulation may require the following excipient functions:

Excipient function	Commercially relevant examples	Formulation purpose
Dilution and compression	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Provides tablet mass and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces sticking and ejection force
Flow aid	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Protects the tablet and improves swallowability
Taste and appearance	Approved colorants, opacifiers, flavor systems	Supports product recognition and consumer acceptance

Ibuprofen’s high dose makes tablet size a commercial constraint. Excessive filler increases swallow burden, while excessive compression can slow disintegration. A direct-compression system using high-functionality microcrystalline cellulose or co-processed excipients can reduce process steps, but blend uniformity remains important because phenylephrine and chlorpheniramine are present at much lower levels than ibuprofen.

Liquid-filled capsules

Liquid-filled capsules offer a stronger differentiation path. A solvent or suspension vehicle can improve ibuprofen dispersion and reduce tablet mass. Potential vehicle systems include polyethylene glycol, propylene glycol, medium-chain triglycerides, or combinations with surfactants and suspending agents.

The main technical risks are:

• Precipitation of one or more actives during storage.
• Capsule-shell brittleness or softening.
• Migration of liquid components into the gelatin shell.
• Cross-reaction between shell components and aldehyde-sensitive ingredients.
• Dose nonuniformity in suspensions.
• Moisture transfer through the capsule shell.

A liquid-filled system can support faster disintegration and a premium presentation, but it requires tighter control of water activity, shell composition, fill viscosity, and long-term compatibility.

Oral liquids

An oral liquid could expand use among adults who cannot swallow tablets, but it is technically more demanding. Ibuprofen requires a suspension or solubilized system, while phenylephrine and chlorpheniramine can be present in solution. Useful excipient categories include:

• Suspending agents such as xanthan gum, microcrystalline cellulose, carboxymethylcellulose, or hypromellose.
• Wetting agents such as polysorbates or poloxamers.
• Buffers to control pH.
• Sweeteners such as sucralose, sorbitol, or high-intensity sweetener combinations.
• Flavor systems that mask ibuprofen bitterness and chlorpheniramine’s medicinal taste.
• Preservatives where permitted and justified.
• Chelating agents to reduce metal-catalyzed degradation.

A sugar-free, alcohol-free suspension is commercially attractive, but it must demonstrate acceptable sedimentation, redispersibility, dosing uniformity, microbial quality, and palatability.

How should an excipient strategy address ingredient compatibility?

The formulation should treat the three active ingredients as a compatibility system rather than as independent components.

Ibuprofen can create poor wetting and dissolution behavior. Particle-size control, surfactant selection, and wet granulation or liquid dispersion technology can improve performance. Phenylephrine hydrochloride is moisture-sensitive in some environments and can contribute to blend segregation because of its low concentration. Chlorpheniramine maleate requires careful control of blend uniformity and taste.

The preferred development sequence is:

1. Establish active-ingredient compatibility with the proposed excipient matrix.
2. Select a manufacturing route that minimizes segregation.
3. Confirm rapid disintegration and dissolution for ibuprofen.
4. Evaluate assay and content uniformity for the low-dose actives.
5. Test packaging under high humidity and accelerated temperature.
6. Conduct sensory testing for taste, odor, mouthfeel, and swallowability.
7. Match the final Drug Facts label to the specific formulation and dosage form.

The strongest commercial formulation is unlikely to be the one with the most excipients. It is the one that achieves consistent dosing, rapid performance, acceptable size, low manufacturing complexity, and clear consumer differentiation.

What formulation patents could protect an Advil Multi-Symptom Cold and Flu product?

Potentially protectable subject matter includes:

• Specific ratios of ibuprofen, phenylephrine, and chlorpheniramine.
• Liquid-fill vehicles that maintain all actives in a stable state.
• Particle-size distributions or micronized ibuprofen.
• Taste-masking systems.
• Fast-disintegrating caplets.
• Stabilized oral suspensions.
• Capsule-shell compositions that reduce migration or brittleness.
• Packaging systems that control moisture.
• Manufacturing methods that improve content uniformity.

A broad composition patent would face significant validity and obviousness pressure because the individual active ingredients and the general combination are established OTC ingredients. More defensible claims would likely focus on a defined excipient combination, a measurable dissolution or stability result, or a manufacturing process with a specific technical effect.

Method-of-use claims are less commercially valuable in a U.S. OTC setting because the principal uses are already reflected in FDA labeling and monograph conditions. Formulation and manufacturing claims are more relevant than therapeutic-use claims.

What is the Orange Book status and exclusivity position?

Advil Multi-Symptom Cold and Flu is an OTC combination product, not a conventional new-drug product relying on an NDA-based market exclusivity period. FDA OTC monograph products generally do not obtain the same Orange Book patent-listing position associated with prescription NDA products.[2]

Protection category	Relevance to the product
NDA exclusivity	Generally not the primary protection mechanism
Orange Book patent listing	Typically limited or unavailable for a monograph-based OTC product
Paragraph IV certification	Usually not the central generic-entry route
OTC monograph compliance	Primary regulatory pathway for eligible ingredients and uses
Formulation patents	Potentially relevant if independently owned and enforceable
Trademark and trade dress	Major commercial protection
Manufacturing know-how	Important for quality, cost, and supply continuity

The FDA’s regulatory position on oral phenylephrine has become a material commercial issue. In 2024, FDA proposed removing oral phenylephrine as an OTC nasal decongestant monograph ingredient after concluding that available data did not support effectiveness at the reviewed doses.[3] A final regulatory action could require reformulation, relabeling, or discontinuation of products that rely on oral phenylephrine for the decongestant indication.

When could Advil Multi-Symptom Cold and Flu lose market exclusivity?

The product does not have a conventional fixed patent-expiration date comparable to a patented prescription medicine. Market protection can erode through:

• Competing private-label products using the same active ingredients.
• Retailer substitution and price competition.
• FDA action affecting oral phenylephrine.
• Trademark dilution or loss of shelf visibility.
• Consumer movement toward single-ingredient products.
• Reformulation by competitors with better taste, smaller dosage units, or easier dosing.

The practical competitive window is therefore determined by brand equity, retail distribution, manufacturing cost, product ratings, and regulatory continuity rather than by one Orange Book patent expiration date.

Which companies are challenging the product commercially?

The main competitive threat comes from store-brand and national-brand OTC products containing overlapping active ingredients. Relevant competitors include retailer private labels, Perrigo-manufactured store brands, CVS Health, Walgreens, Walmart, Target, Rite Aid, and other manufacturers supplying combination cold-and-flu products. Comparable national brands include products from Haleon, Kenvue, Reckitt, and other consumer-health companies.

Competition is strongest in three areas:

1. Price-per-dose comparisons.
2. Seasonal shelf placement.
3. Consumer trust in symptom coverage and dosing simplicity.

Private-label manufacturers can often match the active-ingredient profile while reducing brand and marketing costs. A differentiated excipient system must therefore produce a visible benefit, such as a smaller capsule, better taste, faster disintegration, alcohol-free liquid delivery, or improved dosing convenience.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target five product-development opportunities.

Premium liquid-filled capsules

A stable, low-viscosity fill with improved ibuprofen dispersion could support a premium "easy-to-swallow" or "fast relief" presentation. The commercial value depends on measurable dissolution, acceptable capsule stability, and a meaningful consumer benefit.

Alcohol-free oral suspension

An alcohol-free, sugar-free suspension could address adult consumers with swallowing difficulty and consumers seeking lower-sugar products. The primary development barriers are taste masking and physical stability.

Better flavor systems

Chlorpheniramine and ibuprofen create a difficult taste profile. High-intensity sweeteners, bitterness blockers, encapsulated flavors, and multilayer suspension systems may create a defensible formulation platform.

Child-resistant and adherence-oriented packaging

Unit-dose blister packs, calibrated dosing devices, and day/night packaging can reduce accidental duplicate dosing. Packaging must distinguish Advil Multi-Symptom Cold and Flu from single-ingredient ibuprofen and other acetaminophen-containing products.

Reformulation after phenylephrine action

If FDA finalizes removal of oral phenylephrine from the OTC monograph, manufacturers could pursue a revised combination, a symptom-specific ibuprofen product, or a non-decongestant cold-and-flu formulation. This creates demand for new flavor, suspension, coating, and stability systems, although the product would need new labeling and possibly a different regulatory basis.

How strong is the patent estate for this product?

The likely strength of the product’s intellectual-property position is moderate for brand and manufacturing know-how but limited for broad active-ingredient composition claims. The strongest potential claims would cover:

• A defined liquid vehicle.
• A proprietary taste-masking system.
• A specific low-dose blend-uniformity process.
• A stability package for the three-actives combination.
• A dosage form with demonstrated dissolution or disintegration advantages.

Commercial exclusivity is more likely to come from the Advil trademark, retail relationships, manufacturing scale, and consumer recognition than from a broad patent estate.

What generic launch scenarios exist?

A competitor can pursue several routes:

Launch route	Likely commercial impact
Exact active-ingredient copy	High price pressure; limited differentiation
Same actives in a caplet	Moderate substitution risk
Store-brand liquid-filled capsule	Stronger premium challenge
Sugar-free oral suspension	Expands the addressable consumer segment
Single-ingredient ibuprofen plus separate products	Competes for partial symptom-treatment demand
Reformulated phenylephrine-free product	Could reset the category after FDA action

Retail private-label entry is the most immediate risk because it does not require a complex biosimilar pathway or a Paragraph IV challenge. Biosimilar risk is not applicable because the product contains small-molecule OTC active ingredients, not a biologic.

What are the revenue and licensing opportunities?

Haleon does not generally report Advil Multi-Symptom Cold and Flu revenue as a separately disclosed public segment. Revenue exposure is embedded in the Advil and broader consumer-health portfolio. Seasonal cold-and-flu demand creates substantial fourth-quarter and winter-quarter sensitivity, but product-level revenue cannot be reliably separated from public company reporting.[4]

Licensing opportunities are most credible in:

• Proprietary excipient systems.
• Taste-masking technologies.
• Liquid-fill capsule platforms.
• Pediatric-friendly delivery systems, subject to regulatory eligibility.
• Packaging and dosing systems.
• Regional manufacturing or distribution rights.

An excipient license should be structured around performance specifications, supply continuity, regulatory support, and freedom-to-operate rights. A formulation technology that increases cost without improving the label claim, consumer experience, or manufacturing yield is unlikely to support a durable royalty.

Key Takeaways

• Advil Multi-Symptom Cold and Flu combines ibuprofen, phenylephrine hydrochloride, and chlorpheniramine maleate in a technically demanding OTC formulation.
• The most valuable excipient opportunities involve dissolution, taste masking, stability, liquid-filled capsules, and alcohol-free suspensions.
• Broad active-ingredient composition patents are likely weaker than formulation, process, packaging, and manufacturing claims.
• Traditional Orange Book exclusivity and Paragraph IV litigation are not the main commercial defenses for this OTC product.
• Oral phenylephrine regulatory action is the largest near-term reformulation risk.
• Private-label products represent the principal generic-entry threat.
• Brand strength, retailer access, manufacturing scale, and formulation performance are more important than a conventional patent-expiration date.
• Product-level revenue is not separately disclosed, so commercial exposure must be assessed through Advil and Haleon portfolio data.

FAQs

Can a new excipient create market exclusivity for Advil Multi-Symptom Cold and Flu?

Yes, if the excipient system supports valid patent claims tied to a specific composition, process, stability result, or performance outcome. The claims must provide more than routine substitution of one conventional excipient for another.

Is phenylephrine the main reformulation risk?

Yes. FDA’s proposed finding that oral phenylephrine is not effective at the reviewed OTC doses could force changes to labeling, composition, or market positioning.[3]

Can a generic manufacturer copy the Advil formulation?

A competitor can generally market a product with the same active ingredients if it meets the applicable OTC regulatory requirements. It may not copy protected trademarks, trade dress, proprietary formulation claims, or confidential manufacturing know-how.

Is a liquid-filled capsule commercially superior to a caplet?

Not automatically. It can improve consumer perception, swallowability, and potentially dissolution, but it creates higher requirements for shell compatibility, fill stability, manufacturing controls, and packaging.

Are biosimilar competitors relevant to this product?

No. Advil Multi-Symptom Cold and Flu is a small-molecule OTC combination product. Its relevant competitors are branded generics, private-label products, and reformulated OTC medicines.

References

1. DailyMed. (n.d.). Advil Multi-Symptom Cold and Flu: Drug Facts label. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Food and Drug Administration. (2024). FDA proposes ending use of oral phenylephrine as OTC nasal decongestant ingredient. FDA.
4. Haleon plc. (2024). Annual report 2023. Haleon.